Publications

The EAVI2020 project resulted so far in the following publications:

• Lucar O, Su B, Potard V, Samri A, Autran B, Moog C, Debré P, and Vieillard V. (2017). Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status. EBioMedicine 22 122–132. DOI: 10.1016/j.ebiom.2017.07.007

• Borthwick N, Lin Z, Akahoshi T, Llano A, Silva-Arrieta S, Ahmed T, Dorrell L, Brander C, Murakoshi H, Takiguchi M, and Hanke T. (2017). Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines. PLoS ONE 12(4). DOI: 10.1371/journal.pone.0176418

• Ruiz-Riol D, Berdnik A, Llano B, Mothe C, Gálvez S, Pérez-Álvarez B, Oriol-Tordera A, Olvera S, Silva-Arrieta M, Meulbroek F, Pujol J, Coll J, Martinez-Picado C, Ganoza J, Sanchez G, Gómez T, Wyss-Coray C, and Brander C (2017). Identification of Interleukin-27 (IL-27)/IL-27 Receptor Subunit Alpha as a Critical Immune Axis for In Vivo HIV Control. Journey of Virology 91(16). DOI: 10.1128/JVI.00441-17

• Oriol-Tordera B, Llano A, Ganoza C, Cate S, Hildebrand W, Sanchez J, Calle ML, Brander C, and Olvera A. (2017). Impact of HLA-DRB1 allele polymorphisms on control of HIV infection in a Peruvian MSM cohort. 90(4). DOI: 10.1111/tan.13085

• Wee E.G, Ondondo B, Berglund P, Archer J, McMichael A.J, Baltimore D, Meulen J.H, and Hanke T. (2017).HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells.  Molecular Therapy 25(2). DOI: 10.1016/j.ymthe.2016.12.004

• Capucci S, Wee EG, Schiffner T, LaBranche CC, Borthwick N, Cupo A, Dodd J, Dean H, Sattentau Q, Montefiori D, Klasse P.J, Sanders R.W, Moore J.P, and Hanke T. (2017). HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. PLoS ONE 12(8). DOI: 10.1371/journal.pone.0181886

• Soldemo M and Hedestam G.B.K. (2017). Env-Specific Antibodies in Chronic Infection versus in Vaccination. Frontiers in Immunology 8:1057 DOI: 10.3389/fimmu.2017.01057

• Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye S.W., Moral-Sanchez I.D., McGuire A.T, Yasmeen A, Behrens A, Ozorowski G, van den Kerkhof T.L.G.M., Freund N.T, Dosenovic P, Hua Y, Gitlin A.D., Cupo A, van der Woude P, Golabek M, Sliepen K, Blane T, Kootstra N, van Breemen M.J., Pritchard L.K., Stanfield r.L., Crispin. M, Ward A.B., Stamatatos L, Klasse P.J., Moore J.P, Nemazee D, Nussenzweig M.C, Wilson I.A, and Sanders R.W. (2017). Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. Journal of Experimental Medicine 214(9) DOI: 10.1084/jem.20161160

• Medina-Ramírez M, Sanders R.W, and Sattentau Q.J. (2017).Stabilized HIV-1 envelope glycoprotein trimmers for vaccine use.  Current Opinion HIV AIDS. 12(3). DOI: 10.1097/COH.0000000000000363

• Mahant A, Saubi N, Eto Y, Guitart N, Gatell J.M., Hanke T, and Joseph. J (2017). Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity. Human Vaccines and Immunotherapeutics 13( 8). DOI: 10.1080/21645515.2017.1316911

• Sanders R.W., and Moore J.P. (2017).Native-like Env trimers as a platform for HIV-1 vaccine design.  Immunological Reviews 275. DOI: 10.1111/imr.12481

• van Gils M.J., van den Kerkhof T.L., Ozorowski G, Cottrell C.A., Sok D, Pauthner M, Pallesen J, de Val N, Yasmeen A, de Taeye S.W., Schorcht A, Gumbs S, Johanna I, Saye-Francisco K, Liang C.H., Landais E, Nie X, Pritchard L.K., Crispin M, Kelsoe G, Wilson I.A., Schuitemaker H, Klasse P.J., Moore J.P., Burton D.R., Ward A.B., Sanders R.W. (2016). An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nature Microbiology. 2: 16199. DOI: 10.1038/nmicrobiol.2016.199

• Coss K.P., Vasiljevic S, Pritchard L.K., Krumm S.A., Glaze M, Madzorera S, Moore P.L., Crispin M, and Doores K.J. (2016). HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual. Journal of Virology 90(24). DOI:1128/JVI.01542-16

• Sanchez-Merino A, Fabra-Garcia N, Gonzalez D, Nicolas A, Merino-Mansilla C, Manzardo J, Ambrosioni A, Schultz A, Meyerhans J. R., Mascola J. M., Gatell J, Alcami J. M., Miro E., and Yuste. (2016). Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. Journal of Virology 90(11). DOI: 10.1128/JVI.00049-16

• Behrens A, and Crispin M. (2017). Structural principles controlling HIV envelope glycosylation. Current Opinion in Structural Biology. DOI: 10.1016/j.sbi.2017.03.008

• Temchura V, and Überla K. (2017). Intrastructural help: improving the HIV-1 envelope antibody response induced by virus-like particle vaccines. Current Opinion in HIV and AIDS. 12(3). DOI: 10.1097/COH.0000000000000358

• Hinkula J, Petkov S, Ljungberg K, Hallengärd D, Bråve A, Isaguliants M, Falkeborn T, Sharma S, Liakina V, Robb M, Eller M, Moss B, Biberfeld G, Sandström E, Nilsson C, Markland K, Blomberg P, and Wahren B. (2017). HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV. Heliyon 3(6).  DOI: 10.1016/j.heliyon.2017.e00339

• Kratochvil S, McKay P.F., Kopycinski J.T., Bishop C, Hayes P.J., Muir L, Pinder C.L., Cizmeci D, King D, Aldon Y, Wines B.D., Hogarth M, Chung A.W., Kent S.J., Held K, Geldmacher C, Dally L, Santos N.S., Cole T, Gilmour J, Fidler S, and Shattock R.J. (2017). A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. Frontiers in Immunology 8: DOI: 10.3389/fimmu.2017.00595.

• Stenler K. E., Lundin L, Hansen S, Petkov N, Mozafari M, Isaguliants P, Blomberg C.I.E, Smith D.M, Goldenberg C.H., Chang K. Ljungberg J. Hinkula, and Wahren B. (2017) Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses. Human Vaccines & Immunotherapeutics 13(12). DOI: 10.1080/21645515.2017.1338546

• Behrens A, Weston B.S., and Crispin. M (2017). Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1. Expert Review of Proteomics 14(10). DOI: 10.1080/14789450.2017.1376658

• Olvera A, Martinez J.P., Casadellà M, Llano A, Rosás M, Mothe B, Ruiz-Riol M, Arsequell G, Valencia Gr, Noguera-Julian M, Paredes R, Meyerhans A, and Brander C. (2018). Benzyl-2-Acetamido-2-Deoxy-α-d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy In Vitro. Frontiers in Immunology DOI: 10.3389/fimmu.2017.02010

• Schiffner T, Pallesen J, Russell R.A., Dodd J, de Val N, LaBranche C, Montefiori D, Tomaras G.D., Shen X, Harris S.L., Moghaddam A.E., Moghaddam A.E., Kalyuzhniy O, Sanders R.W., McCoy L.E., Moore J.P., Ward A.B., and Sattentau Q.J. (2018). Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. PLOS Pathogens 14(5). DOI: 10.1371/journal.ppat.1006986

• Elsayed H, Nabi G, McKinstry W.J., Khoo K.K., Mak J, Salazar A.M., Tenbusch M, Temchura V, and U¨ berla K. (2018). Intrastructural help: harnessing T helper cells induced by licensed vaccines for improvement of HIV Env antibody responses to virus-like particle vaccines. Journal of Virology DOI: 10.1128/JVI.00141-18

• González N, McKee K, Lynch RM, Georgiev IS, Jimenez L, Grau E, Kwong P.D., Mascola J.R., and Alcamí, J. (2018). Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term nonprogressors. PLoS ONE 13(3). DOI: 10.1371/journal.pone.0193773

• Aldon Y, McKay P.F., Allen J, Ozorowski G, Felfödiné Lévai R, Tolazzi M, Rogers P, He L, de Val N, Fábián K, Scarlatti G, Zhu J, Ward A.B., Crispin M, and Shattock R.J. (2018). Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers. CelRep 24(12). DOI: 10.1016/j.celrep.2018.08.051

• Cheeseman H.M., Day S, McFarlane L.R., Fleck S, Miller A, Cole T, Sousa-Santos N, Cope A, Cizmeci D, Tolazzi M, Hwekwete E, Hannaman D, Kratochvil S, McKay P.F., Chung A.W., Kent S.J., Cook A, Scarlatti G, Abraham S, Combadiere B, McCormack S, Lewis D.J., and Shattock R.J. (2018). Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine. Human Gene Therapy 29(9). DOI: 10.1089/hum.2018.075

• Anderson J, Olafsdottir T.A., Kratochvil S, McKay P.F., Östensson M, Persson J, Shattock R.J., and Harandi A.M. (2018). Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans. Frontiers in Immunology 9. DOI: 10.3389/fimmu.2018.00301

• Kratochvil S, McKay P.F., Chung A.W., Kent S.J., Gilmour J, and Shattock R.J. (2017). Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination. Frontiers in Immunology 8. DOI: 10.3389/fimmu.2017.01883

• Pinder C.L., Kratochvil S, Cizmeci D, Muir L, Guo Y, Shattock R.J., and McKay P.F., (2017). Isolation and Characterization of Antigen-Specific Plasmablasts Using a Novel Flow Cytometry–Based Ig Capture Assay. Journal of Immunology 199(12) DOI: 10.4049/jimmunol.1701253

• Viegas E.O., Kroidl A, Munseri P.J., Missanga M, Nilsson C, Tembe N, Bauer A, Joachim A, Joseph S, Mann P, Geldmacher C, Fleck S, Stöhr W, Scarlatti G, Aboud S, Bakari M, Maboko L, Hoelscher M, Wahren B, Robb M.L., Weber J, McCormack S, Biberfeld G, Jani I.V., Sandström E, Lyamuya E, and TaMoVac study group. (2018). Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. PLOS ONE 13(11).  DOI: 10.1371/journal.pone.0206838

• Crispin M, Ward A.B., and Wilson I.A. (2018). Structure and Immune Recognition of the HIV Glycan Shield. Annual Review of Biophysics 47(1). DOI: 10.1146/annurev-biophys-060414-034156

• Lopez E, Shattock R.J., Kent S.J., and Chung A.W. (2018). The Multifaceted Nature of Immunoglobulin A and Its Complex Role in HIV. AIDS Research and Human Retroviruses 34(9). DOI: 10.1089/aid.2018.0099

• Moyo N, Vogel A.B., Buus S, Erbar S, Wee E.G., Sahin U, and Hanke T. (2018). Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA. Molecular Therapy Methods & Clinical Development DOI: 10.1016/j.omtm.2018.10.010

• Broset E, Saubi N, Guitart N, Aguilo N, Uranga S, Kilpeläinen A, Eto Y, Hanke T, Gonzalo-Asensio J, Martín C, and Joseph-Munné J. (2019). MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice. Molecular Therapy Methods & Clinical Development DOI: 10.1016/j.omtm.2019.01.014

• Seabright G.E., Doores K.J., Burton D.R., and Crispin M. (2019). Protein and Glycan Mimicry in HIV Vaccine Design. Journal of Molecular Biology DOI: 10.1016/j.jmb.2019.04.016

• Vázquez Bernat N, Corcoran M, Hardt U, Kaduk M, Phad G.E., Martin M, and Karlsson H.G.B. (2019). High-Quality Library Preparation for NGS-Based Immunoglobulin Germline Gene Inference and Repertoire Expression Analysis. Frontiers in Immunology 10. DOI: 10.3389/fimmu.2019.00660

• Heß R, Storcksdieck Genannt Bonsmann M, Lapuente D, Maaske A, Kirschning C, Ruland J, Lepenies B, Hannaman D, Tenbusch M, and Überla K. (2019). Glycosylation of HIV Env Impacts IgG Subtype Responses to Vaccination. Viruses 11(2). DOI: 10.3390/v11020153

• Sliepen K, Han B.W., Bontjer I, Mooij P, Garces F, Behrens A, Rantalainen K, Kumar S, Sarkar A, Brouwer P.J.M., Hua Y, Tolazzi M, Schermer E, Torres J.L., Ozorowski G, van der Woude P, de la Peña A.T., van Breemen M.J., Camacho-Sánchez J.M., Burger J.A., Medina-Ramírez. M, González. N, Alcami.J, LaBranche.C, Scarlatti G, van Gils M.J., Crispin M, Montefiori D.C., Ward A.B., Koopman G, Moore J.P., Shattock R.J., Bogers W.M., Wilson I.A., and Sanders. R.W. (2019). Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nature Communications DOI: 10.1038/s41467-019-10262-5

• Kilpeläinen A, Saubi N, Guitart N, Moyo N, Wee E.G., Ravi K, Hanke T, and Joseph J. (2019). Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice. Frontiers in Immunology 10. DOI: 10.3389/fimmu.2019.00923